semaglutide and gi issues Exploring beyond numeric weight loss: The metabolic effects of Ozempic & the Gut: What

Across roughly 3,400 patients on semaglutide 2.4 mg: Nausea hit 43.9 percent of semaglutide patients vs 16.1 percent on placebo Diarrhea hit 29.7 percent Vomiting hit 24.5 percent Constipation hit 24.2 percent Discontinuation for GI ran 4.3 percent 99.5 percent of all adverse events were non-serious The 2025 FAERS pharmacovigilance signals worth flagging in user reviews include acute pancreatitis, acute kidney injury, gallbladder injury, and NAION (a form of optic neuropathy)

The most commonly reported side effects in clinical practice are local injection-site reactions, mild transient fatigue in the first one to two weeks of use as mitochondrial metabolism adjusts, and, rarely, headache

This might create approval pathways for currently banned peptides or impose stricter controls on the research market

Retatrutide sends three